NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery

News Summary:

• Lilly and NVIDIA launch AI co-innovation lab to tackle drug discovery challenges.
• NVIDIA collaborates with Thermo Fisher to build autonomous lab infrastructure for scalable scientific discovery.
• Chai Discovery, Basecamp Research, Boltz and ecosystem leaders connect NVIDIA BioNeMo, agentic AI and physical AI to scale science and drug discovery.
  

SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- J.P. Morgan Healthcare Conference -- NVIDIA today announced a major expansion of NVIDIA BioNeMo, an open development platform that enables lab-in-the-loop workflows to develop breakthroughs in AI-driven biology and drug discovery.

The life sciences industry generates vast amounts of scientific data. BioNeMo provides the development platform to generate and process data, train, optimize and deploy models — enabling the industry to turn data into a competitive engine for discovery and maximize the probability of success while minimizing R&D costs, which are currently estimated at $300 billion a year.

BioNeMo has now expanded to include:

• New NVIDIA Clara open models, the RNAPro model for RNA structure prediction and the ReaSyn v2 model for ensuring AI-designed drugs are practical to synthesize.
• BioNeMo Recipes to easily accelerate and efficiently scale biological foundation model training, customization and deployment.
• BioNeMo data processing libraries such as nvMolKit, a GPU-accelerated cheminformatics tool for molecular design.
  

“Biology and drug discovery are reaching their transformer moments,” said Kimberly Powell, vice president of healthcare at NVIDIA. “BioNeMo turns experimental data into usable intelligence for AI, so every experiment informs the next. This creates a continuous learning cycle that speeds up discovery and helps researchers build new frontier models to tackle some of biology’s toughest challenges.”

NVIDIA is collaborating with leading life sciences organizations to integrate BioNeMo with laboratory experiments and scientific workflows, enabling the full AI lifecycle for biology and drug discovery — closing the loop between experimentation and AI.

Today, Lilly announced a first-of-its-kind collaboration with NVIDIA to launch a co-innovation lab focused on tackling some of the most enduring challenges in drug discovery. In parallel, Thermo Fisher announced a collaboration with NVIDIA aimed at making scientific instruments intelligent and laboratories increasingly autonomous.